Articles related to HEART FAILURE (HF)

In patients with heart failure and preserved ejection fraction, finerenone demonstrated a 16% reduction in the primary composite endpoint of total worsening heart failure events and cardiovascular death compared to placebo.

A recent randomized controlled trial found that ertugliflozin treatment was associated with a significant reduction in the yearly rate of sustained ventricular arrhythmias (3.5 vs 13.3 events) compared to placebo in patients with heart failure and implantable cardioverter-defibrillators.

Digoxin’s narrow therapeutic window and individual patient variability necessitate careful monitoring and consideration in clinical practice.

The bRIGHT study demonstrates that T-TEER using the TriClip system can lead to sustained TR reduction and quality of life improvements in a diverse, real-world population with advanced tricuspid valve disease.

Rapid optimization of guideline-directed medical therapy in heart failure patients post-discharge was associated with sustained decongestion and improved clinical outcomes at 90 days.

Semaglutide treatment led to more frequent improvement and less frequent deterioration in NYHA functional class compared to placebo in patients with obesity-related HFpEF over 52 weeks.